Trans-Atlantic Trade and Investment Partnership; 
Trans-Pacific Partnership Agreement; 
Trade Promotion Authority;
Columbia-America Free Trade Agreement; H.R. 880, American Research and Competitiveness Act of 2015; 
H.R. 1430, Permanent CFC Look-Through Act;
S. 2260, Expiring Provisions Improvement, Reform, and Efficiency (EXPIRE) Act of 2014;
H.R. 415 & S. 198, Stop Corporate Inversions Act; 
S. 2786, Corporate Inverters Earnings Stripping Reform;
S. 2895, Pay What You Owe Before You Go Act;
H.R. 1809, No Federal Contracts for Corporate Deserters Act;
S. 1946, Tax Relief Extension Act of 2015;
H.R. 1, Tax Reform Act of 2014;
Innovation Promotion Act of 2015 (Not yet introduced);
Administrations Tax Reform and 2016 Budget Proposals; 
Senate and House Committee Tax Reform Proposals; 
Proposals to reform domestic and international tax structures (no bills introduced); 
Senate Finance Committee Tax Reform Working Groups; H.R. 3116, MODDERN Cures Act of 2013; 
S. 3004, Dormant Therapies Act of 2014;
H.R. 406 & S. 1767, Combination Drug Development Incentive Act of 2015; 
H.R. 1537 & S. 1878, Advancing Hope Act of 2015;
S. 1720, Patent Transparency and Improvements Act of 2013;
S. 632, STRONG Patents Act of 2015; 
H.R. 9, Innovation Act;
H.R. 160, Protect Medical Innovation Act of 2015;
S. 214, Preserve Access to Affordable Generics Act of 2013;
H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013;
H.R. 971 & S. 1421, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015; 
Proposals/Initiatives related to international intellectual property protection; H.R. 6, 21st Century Cures Act; 
Discussions to clarify or reform the 340B program; 
Biologics Price Competition and Innovation Act;
H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; 
Public Law 111-148, The Patient Protection and Affordable Care Act; 
Public Law 111-152, The Health Care and Education Reconciliation Act;
H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015;
Proposals to address prescription drug abuse; 
Implementation of The Prescription Drug User Fee Act (PDUFA);
Implementation of The Biosimilars User Fee Act (BsUFA);
H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; 
H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; Policies to enhance patient access to medicines in Medicaid;
Policies to enhance patient access to medicines in Medicare; 
H.R. 2298, Medicare Patient Safety and Drug Abuse Prevention Act;
H.R. 2914, Promoting Integrity in Medicare Act;
H.R. 1190 & S. 141, Protecting Seniors' Access to Medicare Act of 2015;
H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act;
H.R. 3061 & S. 31, Medicare Prescription Drug Price Negotiation Act of 2015;
H.R. 1102 & S. 117, Medicare Prescription Drug Price Negotiation Act;
H.R. 2005 & S. 1083, Medicare Drug Savings Act;
H. R. 3742, Access to Marketplace Insurance Act;
Medicare payment proposals; H.R.2029, Military Construction and Veterans Affairs and Related Agencies Appropriations Act;
P.L. 114-113, Consolidated Appropriations Act, 2016 (H.R. 2029);
H.R. 3762, Restoring Americans' Healthcare Freedom Reconciliation Act of 2015;
Other Labor, Health and Human Services Appropriations (No Bills Introduced); 
H.R. 1078, Food & Drug Administration Safety Over Sequestration Act; 
S. 1413, FDA User Fee Protection Act;
FDAs Changes Being Effected Rule;
TRD - Trade (domestic/foreign) TAX - Taxation/Internal Revenue Code CPT - Copyright/Patent/Trademark HCR - Health Issues MMM - Medicare/Medicaid BUD - Budget/Appropriations
136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR)
ABBVIE, INC.
1399 New York Avenue NW, Suite 600, Washington, DC, 20005, US
ANDREW KAPLAN MICHAEL D BOYD STEPHEN SCANGO HEATHER STRAWN MICHAEL D BOYD ANDREW KAPLAN HEATHER STRAWN JOHN P. FORD ANDREW KAPLAN HEATHER STRAWN MICHAEL D BOYD MICHAEL D BOYD JOHN P. FORD ANDREW KAPLAN HEATHER STRAWN STEPHEN SCANGO JOHN P. FORD ANDREW KAPLAN HEATHER STRAWN STEPHEN SCANGO MICHAEL D BOYD JOHN P. FORD ANDREW KAPLAN HEATHER STRAWN MICHAEL D BOYD STEPHEN SCANGO